RNA活性化
(April 2016). doi:10.18632/oncotarget.8290. PMC 5008410. PMID 27014974. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008410/.
↑ “Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer”. Oncogene 37 (24): 3216–3228. (June 2018). doi:10.1038/s41388-018-0126-2. PMC 6013054. PMID 29511346. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013054/.
↑ “MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL-CEBPA in Patients with Liver Cancer | Business Wire”. www.businesswire.com. 2016年6月6日閲覧。
↑ “First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer - Full Text View - ClinicalTrials.gov”. clinicaltrials.gov. 2016年6月6日閲覧。